AHA 2026: Tirzepatide Improves Key Biomarkers in Obesity-Related Heart Failure
At AHA 2026, tirzepatide showed promise for obesity-related HFpEF, but its role in treating heart failure remains unestablished.
At AHA 2026, tirzepatide showed promise for obesity-related HFpEF, but its role in treating heart failure remains unestablished.